Andrew Berchuck

Overview:

Dr. Andrew Berchuck is Director of the Duke Division of Gynecologic Oncology and holds the James M. Ingram Distinguished Professorship. He is a practicing oncologist who is actively involved in the surgical and chemotherapy management of women with ovarian, endometrial and lower genital tract cancers. This includes minimally invasive laparoscopic surgical approaches. He also has developed a research program that focuses on the molecular-genetic alterations involved in malignant transformation of the ovarian and endometrial epithelium. He has published over 300 peer-reviewed papers in these areas. The objectives of his research include 1) identification of ovarian cancer susceptibility polymorphisms through a population-based case-control molecular epidemiologic study, and 2) use of genomic approaches to elucidate the molecular heterogenetity of ovarian cancer. Thirty fellows and residents have worked in his lab, several of whom are now funded investigators. His research efforts have been recognized nationally and he has received awards for best oral presentation at the annual meetings of both the Society of Gynecologic Oncology and the International Gynecologic Cancer Society. Dr. Berchuck was awarded the Barbara Thomason Ovarian Cancer Research Professorship by the American Cancer Society in 2006. He has served as editor of several books in the field including Principles and Practice of Gynecologic Oncology. Dr. Berchuck also has a major commitment to national activities, and was President of the Society of Gynecologic Oncology in 2008. He served as chair of the scientific advisory committee of the Ovarian Cancer Research Fund (http://www.ocrf.org) in New York City. Finally, he is also head of the steering committee of the international Ovarian Cancer Association Consortium (OCAC), a group of 50 case-control studies that are working together to identify ovarian cancer susceptibility polymorphisms (www.srl.cam.ac.uk/consortia/ocac/index.html).

Positions:

James M. Ingram Distinguished Professor of Gynecologic Oncology

Obstetrics and Gynecology, Gynecologic Oncology

School of Medicine

Professor of Obstetrics and Gynecology

Obstetrics and Gynecology, Gynecologic Oncology

School of Medicine

Chief of Gynecologic Oncology

Obstetrics and Gynecology, Gynecologic Oncology

School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute

School of Medicine

Education:

M.D. 1980

Case Western Reserve University

Grants:

A Role of Multilevel Healthcare Access Dimensions in Ovarian Cancer Disparities

Administered By

Population Health Sciences

Awarded By

National Institutes of Health

Role

Co Investigator

Start Date

February 01, 2019

End Date

April 30, 2024

Endometrial Cancer TCGA Project

Administered By

Obstetrics and Gynecology, Gynecologic Oncology

Awarded By

National Institutes of Health

Role

Principal Investigator

Start Date

May 20, 2010

End Date

March 31, 2015

Discovery of Novel Rare Variants as Ovarian Cancer Susceptibility Factors

Administered By

Obstetrics and Gynecology, Gynecologic Oncology

Role

Principal Investigator

Start Date

August 01, 2016

End Date

July 31, 2019

Discovery of Novel Rare Variants as Ovarian Cancer Susceptibility Factors

Administered By

Obstetrics and Gynecology, Gynecologic Oncology

Awarded By

MD Anderson Cancer Center

Role

Principal Investigator

Start Date

August 01, 2015

End Date

July 31, 2016

TGCA Purchase Order

Administered By

Obstetrics and Gynecology, Gynecologic Oncology

Awarded By

Leidos Biomedical Research, Inc.

Role

Principal Investigator

Start Date

October 30, 2014

End Date

November 12, 2014

Publications:

Endometrial cancer

The prior dichotomous classification of endometrial cancer into high and low risk subtypes based primarily on histology has been shown to be inadequate in predicting outcome and treatment response. More nuanced molecular categorization of these cancers provides improved targeted therapeutic options and a better understanding of the different disease processes.

Authors

Spinosa, D; Montes de Oca, MK; Watson, CH; Berchuck, A; Previs, RA

MLA Citation

Spinosa, D., et al. “Endometrial cancer.” Genomic and Precision Medicine: Oncology, Third Edition, 2022, pp. 191–203. Scopus, doi:10.1016/B978-0-12-800684-9.00014-9.

URI

https://scholars.duke.edu/individual/pub1550798

Source

scopus

Published Date

2022

Start Page

191

End Page

203

DOI

10.1016/B978-0-12-800684-9.00014-9

Modification of the Association Between Frequent Aspirin Use and Ovarian Cancer Risk: A Meta-Analysis Using Individual-Level Data From Two Ovarian Cancer Consortia.

PURPOSE: Frequent aspirin use has been associated with reduced ovarian cancer risk, but no study has comprehensively assessed for effect modification. We leveraged harmonized, individual-level data from 17 studies to examine the association between frequent aspirin use and ovarian cancer risk, overall and across subgroups of women with other ovarian cancer risk factors. METHODS: Nine cohort studies from the Ovarian Cancer Cohort Consortium (n = 2,600 cases) and eight case-control studies from the Ovarian Cancer Association Consortium (n = 5,726 cases) were included. We used Cox regression and logistic regression to assess study-specific associations between frequent aspirin use (≥ 6 days/week) and ovarian cancer risk and combined study-specific estimates using random-effects meta-analysis. We conducted analyses within subgroups defined by individual ovarian cancer risk factors (endometriosis, obesity, family history of breast/ovarian cancer, nulliparity, oral contraceptive use, and tubal ligation) and by number of risk factors (0, 1, and ≥ 2). RESULTS: Overall, frequent aspirin use was associated with a 13% reduction in ovarian cancer risk (95% CI, 6 to 20), with no significant heterogeneity by study design (P = .48) or histotype (P = .60). Although no association was observed among women with endometriosis, consistent risk reductions were observed among all other subgroups defined by ovarian cancer risk factors (relative risks ranging from 0.79 to 0.93, all P-heterogeneity > .05), including women with ≥ 2 risk factors (relative risk, 0.81; 95% CI, 0.73 to 0.90). CONCLUSION: This study, the largest to-date on aspirin use and ovarian cancer, provides evidence that frequent aspirin use is associated with lower ovarian cancer risk regardless of the presence of most other ovarian cancer risk factors. Risk reductions were also observed among women with multiple risk factors, providing proof of principle that chemoprevention programs with frequent aspirin use could target higher-risk subgroups.

Authors

Hurwitz, LM; Townsend, MK; Jordan, SJ; Patel, AV; Teras, LR; Lacey, JV; Doherty, JA; Harris, HR; Goodman, MT; Shvetsov, YB; Modugno, F; Moysich, KB; Robien, K; Prizment, A; Schildkraut, JM; Berchuck, A; Fortner, RT; Chan, AT; Wentzensen, N; Hartge, P; Sandler, DP; O'Brien, KM; Anton-Culver, H; Ziogas, A; Menon, U; Ramus, SJ; Pearce, CL; Wu, AH; White, E; Peters, U; Webb, PM; Tworoger, SS; Trabert, B

MLA Citation

Hurwitz, Lauren M., et al. “Modification of the Association Between Frequent Aspirin Use and Ovarian Cancer Risk: A Meta-Analysis Using Individual-Level Data From Two Ovarian Cancer Consortia.” J Clin Oncol, vol. 40, no. 36, Dec. 2022, pp. 4207–17. Pubmed, doi:10.1200/JCO.21.01900.

URI

https://scholars.duke.edu/individual/pub1529658

PMID

35867953

Source

pubmed

Published In

Journal of Clinical Oncology

Volume

Published Date

2022

Start Page

4207

End Page

4217

DOI

10.1200/JCO.21.01900

Race, Affordability and Utilization of Supportive Care in Ovarian Cancer Patients.

OBJECTIVE: Lack of access to supportive care (SC) among cancer patients have been well documented. However, the role of affordability in this disparity among ovarian cancer (OC) patients remain poorly understood. METHODS: Patients with OC between 2008 and 2015 were identified from the SEER-Medicare dataset. Racial disparities in utilization of SC medications within the six months of OC diagnosis among patients with Medicare Part D coverage was examined. Multivariable log-binomial regression models were used to examine the associations of race, affordability and SC medications after adjusting for clinical covariates among all patients and separately among patients with advanced-stage disease. RESULTS: The study cohort included 3697 patients: 86% non-Hispanic White (NHW), 6% non-Hispanic Black (NHB), and 8% Hispanic. In adjusted models, NHB and Hispanic patients were less likely to receive antidepressants compared to NHW patients (NHB: aOR 0.46; 95% CI 0.33-0.63 and Hispanic: aOR 0.79; 95% CI 0.63-0.99). This association persisted for NHB patients with advanced-stage disease (aOR 0.42; 95% CI 0.28-0.62). Patients dual enrolled in Medicaid were more likely to receive antidepressants (overall: aOR 1.34; 95% CI 1.17-1.53 and advanced-stage: aOR 1.29; 95% CI 1.10-1.52). However, patients residing in areas with higher vs. lower proportions of lower educated adults (overall: aOR 0.82; 95% CI 0.70-0.97 and advanced-stage: aOR 0.82; 95% CI 0.68-0.99) were less likely to receive antidepressants. CONCLUSION: Black OC patients and those living in lower educated areas were less likely to receive antidepressants as SC. Given the importance of post-primary treatment quality of life for cancer patients, interventions are needed to enhance equitable access to SC.

Authors

Anyanwu, MC; Ohamadike, O; Wilson, LE; Meernik, C; Huang, B; Pisu, M; Liang, M; Previs, RA; Joshi, A; Ward, KC; Tucker, T; Schymura, MJ; Berchuck, A; Akinyemiju, T

MLA Citation

Anyanwu, Mercy C., et al. “Race, Affordability and Utilization of Supportive Care in Ovarian Cancer Patients.” J Pain Symptom Manage, vol. 64, no. 6, Dec. 2022, pp. 537–45. Pubmed, doi:10.1016/j.jpainsymman.2022.08.021.

URI

https://scholars.duke.edu/individual/pub1535157

PMID

36058401

Source

pubmed

Published In

J Pain Symptom Manage

Volume

Published Date

2022

Start Page

537

End Page

545

DOI

10.1016/j.jpainsymman.2022.08.021

Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study.

BACKGROUND: Recently, we showed a >60% difference in 5-year survival for patients with tubo-ovarian high-grade serous carcinoma (HGSC) when stratified by a 101-gene mRNA expression prognostic signature. Given the varied patient outcomes, this study aimed to translate prognostic mRNA markers into protein expression assays by immunohistochemistry and validate their survival association in HGSC. METHODS: Two prognostic genes, FOXJ1 and GMNN, were selected based on high-quality antibodies, correlation with protein expression and variation in immunohistochemical scores in a preliminary cohort (n = 134 and n = 80, respectively). Six thousand four hundred and thirty-four (FOXJ1) and 5470 (GMNN) formalin-fixed, paraffin-embedded ovarian neoplasms (4634 and 4185 HGSC, respectively) represented on tissue microarrays from the Ovarian Tumor Tissue Analysis consortium underwent immunohistochemical staining and scoring, then univariate and multivariate survival analysis. RESULTS: Consistent with mRNA, FOXJ1 protein expression exhibited a linear, increasing association with improved overall survival in HGSC patients. Women with >50% expression had the most favourable outcomes (HR = 0.78, 95% CI 0.67-0.91, p < 0.0001). GMNN protein expression was not significantly associated with overall HSGC patient survival. However, HGSCs with >35% GMNN expression showed a trend for better outcomes, though this was not significant. CONCLUSION: We provide foundational evidence for the prognostic value of FOXJ1 in HGSC, validating the prior mRNA-based prognostic association by immunohistochemistry.

Authors

Weir, A; Kang, E-Y; Meagher, NS; Nelson, GS; Ghatage, P; Lee, C-H; Riggan, MJ; Gentry-Maharaj, A; Ryan, A; Singh, N; Widschwendter, M; Alsop, J; Anglesio, MS; Beckmann, MW; Berger, J; Bisinotto, C; Boros, J; Brand, AH; Brenton, JD; Brooks-Wilson, A; Carney, ME; Cunningham, JM; Cushing-Haugen, KL; Cybulski, C; Elishaev, E; Erber, R; Fereday, S; Fischer, A; Paz-Ares, L; Gayarre, J; Gilks, BC; Grube, M; Harnett, PR; Harris, HR; Hartmann, A; Hein, A; Hendley, J; Hernandez, BY; Heublein, S; Huang, Y; Huzarski, T; Jakubowska, A; Jimenez-Linan, M; Kennedy, CJ; Kommoss, FKF; Koziak, JM; Kraemer, B; Le, ND; Lesnock, J; Lester, J; Lubiński, J; Menkiszak, J; Ney, B; Olawaiye, A; Orsulic, S; Osorio, A; Robles-Díaz, L; Ruebner, M; Shah, M; Sharma, R; Shvetsov, YB; Steed, H; Talhouk, A; Taylor, SE; Traficante, N; Vierkant, RA; Wang, C; Wilkens, LR; Winham, SJ; Benitez, J; Berchuck, A; Bowtell, DD; Candido Dos Reis, FJ; Cook, LS; DeFazio, A; AOCs group,; Doherty, JA; Fasching, PA; García, MJ; Goode, EL; Goodman, MT; Gronwald, J; Huntsman, DG; Karlan, BY; Kommoss, S; Modugno, F; Schildkraut, JM; Sinn, H-P; Staebler, A; Kelemen, LE; Ford, CE; Menon, U; Pharoah, PDP; Köbel, M; Ramus, SJ

MLA Citation

Weir, Ashley, et al. “Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study.” Br J Cancer, Nov. 2022. Pubmed, doi:10.1038/s41416-022-02014-y.

URI

https://scholars.duke.edu/individual/pub1555552

PMID

36323878

Source

pubmed

Published In

Br J Cancer

Published Date

2022

DOI

10.1038/s41416-022-02014-y

Effects of risk factors for ovarian cancer in women with and without endometriosis.

OBJECTIVE: To evaluate the associations between 10 well-established ovarian cancer risk factors and risk of ovarian cancer among women with vs. without endometriosis. DESIGN: Pooled analysis of 9 case-control studies in the Ovarian Cancer Association Consortium. SETTING: Population-based. PATIENT(S): We included 8,500 women with ovarian cancer, 13,592 control women. INTERVENTION(S): Ten well-established ovarian cancer risk factors. MAIN OUTCOME MEASURE(S): Risk of ovarian cancer for women with and without endometriosis. RESULT(S): Most risk factor-ovarian cancer associations were similar when comparing women with and without endometriosis, and no interactions were statistically significant. However, body mass index (BMI) 25-<30 kg/m2 was associated with increased ovarian cancer risk among women with endometriosis (odds ratio [OR] = 1.27, 95% confidence interval [CI] 1.00-1.60), but not associated with the risk among women without endometriosis (OR = 0.97; 95% CI, 0.91-1.05) when compared with BMI 18.5-<25 kg/m2; an increased risk was observed for a BMI ≥30 kg/m2, although there was little difference comparing women with endometriosis (OR = 1.21; 95% CI, 0.94-1.57) to women without (OR = 1.13; 95% CI, 1.04-1.22) (P-interaction = .51). Genital talcum powder use and long-term menopausal estrogen-only therapy use showed increased ovarian cancer risk, but risk appeared greater for those with endometriosis vs. those without (genital talcum powder: OR = 1.38; 95% CI, 1.04-1.84 vs. OR = 1.12; 95% CI, 1.01-1.25, respectively; ≥10 years of estrogen-only therapy: OR = 1.88; 95% CI, 1.09-3.24 vs. OR = 1.42; 95% CI, 1.14-1.76, respectively); neither of these interactions were statistically significant (P-interaction = .65 and P-interaction = .96, respectively). CONCLUSION(S): The associations between ovarian cancer and most risk factors were similar among women with and without endometriosis. However, there was some suggestion of differences by endometriosis status for BMI, menopausal hormone therapy use, and genital talcum powder use, highlighting the complexity of ovarian cancer etiology.

Authors

Phung, MT; Muthukumar, A; Trabert, B; Webb, PM; Jordan, SJ; Terry, KL; Cramer, DW; Titus, LJ; Risch, HA; Doherty, JA; Harris, HR; Goodman, MT; Modugno, F; Moysich, KB; Jensen, A; Kjaer, SK; Anton-Culver, H; Ziogas, A; Berchuck, A; Khoja, L; Wu, AH; Pike, MC; Pearce, CL; Lee, AW

MLA Citation

Phung, Minh Tung, et al. “Effects of risk factors for ovarian cancer in women with and without endometriosis.” Fertil Steril, vol. 118, no. 5, Nov. 2022, pp. 960–69. Pubmed, doi:10.1016/j.fertnstert.2022.07.019.

URI

https://scholars.duke.edu/individual/pub1553219

PMID

36182623

Source

pubmed

Published In

Fertility and Sterility

Volume

118

Published Date

2022

Start Page

960

End Page

969

DOI

10.1016/j.fertnstert.2022.07.019

Research Areas:

3' Untranslated Regions

3-Oxo-5-alpha-Steroid 4-Dehydrogenase

5-Lipoxygenase-Activating Proteins

ABO Blood-Group System

ATP-Binding Cassette, Sub-Family B, Member 1

Acetaminophen

Actins

Actomyosin

Actuarial Analysis

Adaptor Proteins, Signal Transducing

Adenocarcinoma

Adenocarcinoma, Clear Cell

Adenocarcinoma, Mucinous

Adnexa Uteri

Adnexal Diseases

Adolescent

Adult

African Americans

African Continental Ancestry Group

Age Distribution

Age Factors

Age of Onset

Aged

Aged, 80 and over

Alcohol Dehydrogenase

Algorithms

Alkylating Agents

Alleles

Alternative Splicing

Americas

Amidohydrolases

Amino Acid Sequence

Aminopeptidases

Amnion

Analysis of Variance

Anemia

Aneuploidy

Angiogenic Proteins

Animals

Anthropometry

Anti-Inflammatory Agents, Non-Steroidal

Antibodies

Antibodies, Monoclonal

Antibodies, Monoclonal, Humanized

Antibodies, Neoplasm

Antidepressive Agents

Antigens, CD

Antigens, CD31

Antigens, CD45

Antigens, CD80

Antigens, Tumor-Associated, Carbohydrate

Antineoplastic Agents

Antineoplastic Agents, Phytogenic

Antineoplastic Combined Chemotherapy Protocols

Apolipoprotein A-I

Apoptosis

Apoptosis Regulatory Proteins

Arylamine N-Acetyltransferase

Ascites

Ascitic Fluid

Autophagy

Azacitidine

B7-1 Antigen

BRCA1 Protein

BRCA2 Protein

Base Sequence

Bayes Theorem

Binding Sites

Biopsy

Biopsy, Needle

Blood Coagulation

Blood Coagulation Disorders

Blood Coagulation Tests

Blood Loss, Surgical

Blood Transfusion

Blotting, Northern

Blotting, Southern

Blotting, Western

Body Height

Body Mass Index

Bone Marrow Transplantation

Brachytherapy

Brain Neoplasms

Breast

Breast Neoplasms

CA-125 Antigen

Cadherins

Caloric Restriction

Cancer

Carbon-Nitrogen Ligases

Carboplatin

Carcinoembryonic Antigen

Carcinoma

Carcinoma in Situ

Carcinoma, Adenoid Cystic

Carcinoma, Endometrioid

Carcinoma, Papillary

Carcinoma, Signet Ring Cell

Carcinoma, Small Cell

Carcinoma, Squamous Cell

Carcinosarcoma

Carrier Proteins

Case-Control Studies

Caspase 3

Caspase 8

Catalytic Domain

Cell Adhesion

Cell Culture Techniques

Cell Cycle

Cell Cycle Proteins

Cell Division

Cell Growth Processes

Cell Line

Cell Line, Transformed

Cell Line, Tumor

Cell Lineage

Cell Movement

Cell Proliferation

Cell Shape

Cell Survival

Cell Transformation, Neoplastic

Cells, Cultured

Cervix Uteri

Cesarean Section

Chemotherapy

Chemotherapy, Adjuvant

Chi-Square Distribution

Chickens

Child

Child, Preschool

Chloramphenicol O-Acetyltransferase

Choriocarcinoma

Chorionic Gonadotropin

Chromatin

Chromatography, Affinity

Chromatography, Liquid

Chromium

Chromium Compounds

Chromosome Aberrations

Chromosome Deletion

Chromosome Mapping

Chromosomes, Human, Pair 1

Chromosomes, Human, Pair 10

Chromosomes, Human, Pair 17

Chromosomes, Human, Pair 18

Chromosomes, Human, Pair 19

Chromosomes, Human, Pair 2

Chromosomes, Human, Pair 3

Chromosomes, Human, Pair 4

Chromosomes, Human, Pair 5

Chromosomes, Human, Pair 7

Chromosomes, Human, Pair 8

Chromosomes, Human, Pair 9

Cisplatin

Clinical Competence

Clinical Trials as Topic

Clinical Trials, Phase I as Topic

Clinical Trials, Phase II as Topic

Clone Cells

Cloning, Molecular

Cluster Analysis

Codon

Cohort Studies

Coitus

Colectomy

Collagen

Colon

Colon, Sigmoid

Colonic Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms, Hereditary Nonpolyposis

Combined Modality Therapy

Comparative Effectiveness Research

Comparative Genomic Hybridization

Compliance

Condylomata Acuminata

Confidence Intervals

Confounding Factors (Epidemiology)

Contraception

Contraceptives, Oral

Contraceptives, Oral, Combined

Contraceptives, Oral, Hormonal

Cooperative Behavior

Cost-Benefit Analysis

Counseling

CpG Islands

Culture Media

Cyclin E

Cyclin-Dependent Kinase Inhibitor p16

Cyclin-Dependent Kinase Inhibitor p21

Cyclin-Dependent Kinases

Cyclins

Cyclophosphamide

Cystadenocarcinoma

Cystadenocarcinoma, Papillary

Cystadenocarcinoma, Serous

Cystadenoma, Mucinous

Cystadenoma, Serous

Cysts

Cytochrome P-450 CYP1A1

Cytochrome P-450 CYP3A

Cytokines

Cytostatic Agents

DNA

DNA (Cytosine-5-)-Methyltransferase

DNA (Cytosine-5-)-Methyltransferases

DNA Copy Number Variations

DNA Damage

DNA Fingerprinting

DNA Helicases

DNA Ligases

DNA Methylation

DNA Mismatch Repair

DNA Mutational Analysis

DNA Polymerase II

DNA Primers

DNA Repair

DNA, Complementary

DNA, Neoplasm

DNA, Satellite

DNA, Single-Stranded

DNA-Binding Proteins

Dactinomycin

Data Collection

Decision Support Techniques

Decision Trees

Deoxyribonucleases, Type II Site-Specific

Depression, Chemical

Dermatologic Surgical Procedures

Developed Countries

Diacylglycerol Kinase

Diagnosis, Differential

Diet

Dietary Supplements

Diffusion of Innovation

Dihydrouracil Dehydrogenase (NADP)

Dinoprostone

Diploidy

Discriminant Analysis

Disease Models, Animal

Disease Progression

Disease-Free Survival

Diseases

Dormancy

Dosage Compensation, Genetic

Dose-Response Relationship, Drug

Down-Regulation

Doxorubicin

Drug Administration Schedule

Drug Combinations

Drug Design

Drug Resistance

Drug Resistance, Multiple

Drug Resistance, Neoplasm

Drug Synergism

E2F Transcription Factors

Early Detection of Cancer

Education, Medical, Graduate

Eflornithine

Eggs

Electrophoresis, Polyacrylamide Gel

Endometrial Hyperplasia

Endometrial Neoplasms

Endometriosis

Endometrium

Endosomal Sorting Complexes Required for Transport

Environmental Exposure

Enzyme Induction

Enzyme Inhibitors

Enzyme-Linked Immunosorbent Assay

Epidermal Growth Factor

Epigenesis, Genetic

Epigenomics

Epithelial Cells

Epithelium

Epitopes

Epoxide Hydrolases

Estradiol

Estrogen Antagonists

Estrogen Receptor alpha

Estrogen Receptor beta

Estrogen Replacement Therapy

Estrogens

Ethics, Medical

Ethnic Groups

Etoposide

Europe

European Continental Ancestry Group

Evaluation Studies as Topic

Exome

Exons

Extracellular Space

Factor IX

Fallopian Tube Neoplasms

Fallopian Tubes

Family planning

Fatigue

Fellowships and Scholarships

Female

Fetal Diseases

Fibrin Fibrinogen Degradation Products

Fibroblast Growth Factor 2

Fibroblast Growth Factors

Fibroblasts

Fibronectins

Fistula

Flow Cytometry

Fluorescent Antibody Technique

Fluorine Radioisotopes

Fluorodeoxyglucose F18

Folate Receptor 1

Folate Receptors, GPI-Anchored

Folic Acid

Follow-Up Studies

Forecasting

Formaldehyde

Frozen Sections

G1 Phase

GPI-Linked Proteins

GTP Phosphohydrolases

GTP-Binding Proteins

Galectin 1

Galectin 3

Gastrointestinal Diseases

Gene Amplification

Gene Deletion

Gene Dosage

Gene Expression

Gene Expression Profiling

Gene Expression Regulation

Gene Expression Regulation, Enzymologic

Gene Expression Regulation, Neoplastic

Gene Frequency

Gene Silencing

Gene Transfer Techniques

Gene-Environment Interaction

Genes, BRCA1

Genes, BRCA2

Genes, Neoplasm

Genes, Tumor Suppressor

Genes, cdc

Genes, fms

Genes, p16

Genes, p53

Genes, ras

Genetic Association Studies

Genetic Heterogeneity

Genetic Linkage

Genetic Loci

Genetic Markers

Genetic Predisposition to Disease

Genetic Testing

Genetic Therapy

Genetic Variation

Genetics

Genital Diseases, Female

Genital Neoplasms, Female

Genome, Human

Genome-Wide Association Study

Genomic Imprinting

Genomic Instability

Genomics

Genotype

Germ-Line Mutation

Glycoproteins

Gonadotropins

Granulocyte Colony-Stimulating Factor

Gravity Suits

Great Britain

Green Fluorescent Proteins

Growth Inhibitors

Growth Substances

Gynecologic Surgical Procedures

Gynecology

Half-Life

Haplotypes

HeLa Cells

Head and Neck Neoplasms

Health Care Costs

Health Planning Guidelines

Health Resources

Hemagglutinins

Hemorrhage

Heparin

Hepatocyte Nuclear Factor 1-beta

Heterocyclic Compounds with 4 or More Rings

Heterocyclic Compounds, 4 or More Rings

Heterozygote

Histones

Homeodomain Proteins

Homozygote

Hormone Replacement Therapy

Hormones

Humans

Hybrid Cells

Hydatidiform Mole

Hydrolysis

Hyperthermia, Induced

Hysterectomy

Image Processing, Computer-Assisted

Immunity

Immunoassay

Immunoblotting

Immunoenzyme Techniques

Immunohistochemistry

Immunologic Factors

Immunoradiometric Assay

Immunosuppressive Agents

Immunotherapy

Immunotoxins

In Situ Hybridization

Incidence

Infant

Infant, Newborn

Infection

Inflammation

Infusions, Parenteral

Injections, Intramuscular

Insulin-Like Growth Factor Binding Protein 1

Insulin-Like Growth Factor Binding Protein 2

Insulin-Like Growth Factor Binding Protein 3

Insulin-Like Growth Factor Binding Proteins

Insulin-Like Growth Factor I

Insulin-Like Growth Factor II

Integrins

Intercellular Signaling Peptides and Proteins

Interferon-gamma

Interleukin-1

Interleukin-18

Interleukin-1alpha

Interleukin-6

International Agencies

International Cooperation

Internship and Residency

Interviews as Topic

Intracellular Signaling Peptides and Proteins

Intraoperative Complications

Introns

Kaplan-Meier Estimate

Keratins

Ki-67 Antigen

Kidney Diseases

Kinetics

Laminin

Laparoscopy

Laparotomy

Leiomyoma

Leiomyosarcoma

Length of Stay

Leucine Zippers

Leukocyte Common Antigens

Life Expectancy

Life Tables

Linear Models

Linkage Disequilibrium

Liver Diseases

Logistic Models

Longitudinal Studies

Loss of Heterozygosity

Lovastatin

Luciferases

Luminescent Proteins

Lung Diseases

Lung Neoplasms

Lymph Node Excision

Lymph Nodes

Lymphatic Diseases

Lymphatic Metastasis

Lymphedema

Lymphocyte Activation

Lymphocytes

Lymphocytes, Tumor-Infiltrating

Lysophospholipids

MAP Kinase Kinase 4

MAP Kinase Signaling System

Macaca fascicularis

Macrophage Colony-Stimulating Factor

Magnetics

Male

Mammary Neoplasms, Experimental

Marketing

Markov Chains

Matrix Metalloproteinase 1

Maximum Tolerated Dose

Medical History Taking

Medical Oncology

Medicine

Mefenamic Acid

Membrane Glycoproteins

Membrane Proteins

Membrane Transport Proteins

Menarche

Menopause

Menstrual Cycle

Menstruation Disturbances

Meta-Analysis as Topic

Metabolic Clearance Rate

Methods

Methotrexate

Methylation

Methylenetetrahydrofolate Dehydrogenase (NADP)

Mice

Mice, Inbred BALB C

Mice, Nude

MicroRNAs

Microarray Analysis

Microfilament Proteins

Micromanipulation

Microsatellite Instability

Microsatellite Repeats

Microscopy, Atomic Force

Microscopy, Confocal

Microscopy, Electron

Microspheres

Middle Aged

Mitochondrial Proteins

Mitosis

Mitotic Index

Mixed Tumor, Mesodermal

Mixed Tumor, Mullerian

Models, Biological

Models, Economic

Models, Genetic

Models, Statistical

Molecular Conformation

Molecular Sequence Data

Molecular Targeted Therapy

Molecular Weight

Morbidity

Mucin-1

Mullerian Ducts

Multicenter Studies as Topic

Multivariate Analysis

Muscle, Skeletal

MutS Homolog 2 Protein

Mutagenesis, Insertional

Mutation

Mycobacterium bovis

Myelin Proteins

Myelin and Lymphocyte-Associated Proteolipid Proteins

Myometrium

Myosin Type II

N-Acetylgalactosaminyltransferases

NAD(P)H Dehydrogenase (Quinone)

NF-kappa B

Neoplasm Grading

Neoplasm Invasiveness

Neoplasm Metastasis

Neoplasm Proteins

Neoplasm Recurrence, Local

Neoplasm Staging

Neoplasm Transplantation

Neoplasm, Residual

Neoplasms

Neoplasms, Cystic, Mucinous, and Serous

Neoplasms, Germ Cell and Embryonal

Neoplasms, Glandular and Epithelial

Neoplasms, Multiple Primary

Neoplasms, Second Primary

Neoplastic Stem Cells

Neoplastic Syndromes, Hereditary

Neovascularization, Pathologic

Nerve Tissue Proteins

Neural Networks (Computer)

Neuropeptides

Neutropenia

Nicotinic Acids

North America

North Carolina

Nuclear Proteins

Nuclear Receptor Co-Repressor 1

Nuclear Receptor Co-Repressor 2

Nucleic Acid Heteroduplexes

Nucleic Acid Hybridization

Nutrition Disorders

Obesity

Observer Variation

Odds Ratio

Oligodeoxyribonucleotides

Oligonucleotide Array Sequence Analysis

Oligonucleotide Probes

Omentum

Oncogene Proteins, Viral

Oncogenes

Oncology Service, Hospital

Ornithine Decarboxylase

Ovarian Cysts

Ovarian Diseases

Ovarian Neoplasms

Ovariectomy

Ovary

Oviducts

Ovulation

Oxytocin

P-Glycoprotein

PTEN Phosphohydrolase

Paclitaxel

Pain, Postoperative

Palliative Care

Papillomaviridae

Paraffin Embedding

Parity

Patient Acceptance of Health Care

Patient Selection

Pedigree

Pelvic Exenteration

Pelvic Neoplasms

Pelvis

Peptide Elongation Factor Tu

Peptide Termination Factors

Peptides

Peripheral Nervous System Diseases

Peritoneal Cavity

Peritoneal Diseases

Peritoneal Lavage

Peritoneal Neoplasms

Peritoneum

Peritonitis, Tuberculous

Pharmacogenetics

Phenotype

Phosphates

Phosphatidate Phosphatase

Phosphatidylinositol 3-Kinases

Phosphoproteins

Phosphoric Monoester Hydrolases

Phosphorus Radioisotopes

Phosphorylation

Physical Examination

Pilot Projects

Piperidines

Placenta Accreta

Platelet Endothelial Cell Adhesion Molecule-1

Platelet-Derived Growth Factor

Platinum

Platinum Compounds

Ploidies

Pneumoperitoneum

Point Mutation

Poly(ADP-ribose) Polymerases

Polymerase Chain Reaction

Polymorphism, Genetic

Polymorphism, Restriction Fragment Length

Polymorphism, Single Nucleotide

Polymorphism, Single-Stranded Conformational

Population Dynamics

Population Surveillance

Postmenopause

Postoperative Complications

Postoperative Period

Powders

Practice Guidelines as Topic

Prealbumin

Precancerous Conditions

Precipitin Tests

Predictive Value of Tests

Pregnancy

Pregnancy Complications

Pregnancy Tests

Pregnancy Trimester, Second

Premenopause

Prenatal Diagnosis

Preoperative Care

Prevalence

Principal Component Analysis

Probability

Progesterone

Progestins

Prognosis

Proliferating Cell Nuclear Antigen

Promoter Regions, Genetic

Proportional Hazards Models

Prospective Studies

Prostaglandins

Prostaglandins E

Prostatic Neoplasms

Protamine Kinase

Protective Agents

Protein Array Analysis

Protein Isoforms

Protein Kinase C

Protein Kinase C-delta

Protein Kinase Inhibitors

Protein Precursors

Protein Processing, Post-Translational

Protein Structure, Tertiary

Protein Tyrosine Phosphatases

Protein-Serine-Threonine Kinases

Protein-Tyrosine Kinases

Proteins

Proteoglycans

Proteolipids

Proteomics

Proto-Oncogene Proteins

Proto-Oncogene Proteins B-raf

Proto-Oncogene Proteins c-bcl-2

Proto-Oncogene Proteins c-myb

Proto-Oncogene Proteins pp60(c-src)

Proto-Oncogenes

Purines

Pyrimidines

Quality Control

Quality of Life

Quality-Adjusted Life Years

Quantitative Trait Loci

Questionnaires

Quinone Reductases

RNA

RNA Splicing

RNA, Antisense

RNA, Messenger

RNA, Neoplasm

RNA, Small Interfering

RNA, Untranslated

ROC Curve

Radiation Injuries

Radioimmunoassay

Radioimmunoprecipitation Assay

Radiopharmaceuticals

Radiotherapy

Radiotherapy, Adjuvant

Randomized Controlled Trials as Topic

Rats

Rats, Sprague-Dawley

Real-Time Polymerase Chain Reaction

Receptor Protein-Tyrosine Kinases

Receptor, Epidermal Growth Factor

Receptor, IGF Type 2

Receptor, erbB-2

Receptors, Androgen

Receptors, Calcitriol

Receptors, Cell Surface

Receptors, Estrogen

Receptors, Growth Factor

Receptors, Interleukin-1

Receptors, Interleukin-2

Receptors, Laminin

Receptors, Progesterone

Receptors, Transforming Growth Factor beta

Receptors, Tumor Necrosis Factor

Reconstructive Surgical Procedures

Rectus Abdominis

Recurrence

Reference Values

Registries

Regression Analysis

Remission Induction

Reoperation

Repetitive Sequences, Amino Acid

Repetitive Sequences, Nucleic Acid

Repressor Proteins

Reproducibility of Results

Reproductive History

Retinoblastoma Protein

Retirement

Retrospective Studies

Reverse Transcriptase Polymerase Chain Reaction

Ricin

Risk

Risk Assessment

Risk Factors

Risk Reduction Behavior

Robotics

SEER Program

Sarcoma

Second-Look Surgery

Selective Estrogen Receptor Modulators

Sensitivity and Specificity

Sequence Analysis, DNA

Sequence Deletion

Serpins

Signal Transduction

Skin

Societies, Medical

Societies, Scientific

Socioeconomic Factors

Solubility

Specialization

Spheroids, Cellular

Staining and Labeling

Statistics, Nonparametric

Staurosporine

Sterilization, Tubal

Stimulation, Chemical

Stromal Cells

Sulfites

Surgical Flaps

Surgical Wound Dehiscence

Surgical Wound Infection

Surveys and Questionnaires

Survival

Survival Analysis

Survival Rate

Survivors

Sutures

T-Lymphocytes, Regulatory

TNF-Related Apoptosis-Inducing Ligand

Talc

Tamoxifen

Tandem Mass Spectrometry

Taxoids

Telomerase

Telomere

Terminal Care

Testis

Tetradecanoylphorbol Acetate

Tetrahydronaphthalenes

Therapies, Investigational

Thiazoles

Thigh

Thioguanine

Thiophenes

Thiotepa

Thrombocytosis

Thrombophlebitis

Thrombosis

Thrombospondin 1

Thymidine

Thymidylate Synthase

Time Factors

Tissue Array Analysis

Tissue Distribution

Tissue Embedding

Tissue Fixation

Tomography, Emission-Computed

Tomography, X-Ray Computed

Trans-Activators

Transcription Factors

Transcription, Genetic

Transcriptional Activation

Transfection

Transforming Growth Factor alpha

Transforming Growth Factor beta

Transforming Growth Factor beta1

Transforming Growth Factors

Transplantation, Autologous

Treatment Outcome

Tretinoin

Trinucleotide Repeats

Tritium

Trophoblastic Neoplasms

Tumor Cells, Cultured

Tumor Markers, Biological

Tumor Necrosis Factor-alpha

Tumor Suppressor Protein p53

Tumor Suppressor Proteins

United Kingdom

United States

Up-Regulation

Urologic Diseases

Utah

Uterine Cervical Diseases

Uterine Cervical Incompetence

Uterine Cervical Neoplasms

Uterine Hemorrhage

Uterine Neoplasms

Uterine Rupture

Uterus

Vagina

Vaginal Fistula

Vaginal Neoplasms

Vaginal Smears

Vanadates

Vascular Endothelial Growth Factor A

Vascular Endothelial Growth Factor Receptor-1

Venous Thrombosis

Vincristine

Vulva

Vulvar Neoplasms

Wound Healing

X Chromosome

X-Linked Inhibitor of Apoptosis Protein

Xenobiotics

YY1 Transcription Factor

Young Adult

alpha-Fetoproteins

bcl-Associated Death Protein

ras Proteins

rho GTP-Binding Proteins

src-Family Kinases

James M. Ingram Distinguished Professor of Gynecologic Oncology

Contact:

Profile

https://scholars.duke.edu/person/berch001

Email

berch001@mc.duke.edu

25171 Morris Bldg, Durham, NC 27710

Box 3079 Med Ctr, Durham, NC 27710